Search Medical Condition
Please enter condition
Please choose location from dropdown

Szabadsag, Hungary Clinical Trials

A listing of Szabadsag, Hungary clinical trials actively recruiting patients volunteers.

RESULTS

Found (375) clinical trials

The purpose of this study is to evaluate itacitinib or placebo in combination with corticosteroids as first-line treatment of participants with Grade II to IV acute graft-versus-host disease (aGVHD).

Phase

4.01 miles

Learn More »

Evaluating QTc PK Safety of Gemtuzumab Ozogamicin (GO) in Patients With CD33+ R/R AML

This is a singlearm, openlabel, Phase 4 study evaluating the effect of GO on the QTc, pharmacokinetics, safety, and immunogenicity of GO as a singleagent monotherapy in adult and pediatric patients with relapsed or refractory CD33positive AML. Approximately 50 adult (age >=18 years) and 6 pediatric (12 years =< age ...

Phase

4.01 miles

Learn More »

Study to Assess Efficacy and Safety of Baloxavir Marboxil In Combination With Standard-of-Care Neuraminidase Inhibitor In Hospitalized Participants With Severe Influenza

This study will evaluate the efficacy, safety, and pharmacokinetics of baloxavir marboxil in combination with a standard-of-care (SOC) neuraminidase inhibitor (NAI) (i.e., oseltamivir, zanamivir, or peramivir) compared with a matching placebo in combination with a SOC NAI in hospitalized patients with influenza.

Phase

4.01 miles

Learn More »

A Study of Ustekinumab in Participants With Active Systemic Lupus Erythematosus

This study evaluates the efficacy, safety, and tolerability of ustekinumab in participants with active SLE according to Systemic Lupus International Collaborating Clinics (SLICC) criteria Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score greater than (>=) 6, despite receiving one or more standard-of-care treatments (example, immunomodulators, antimalarial drugs, and/or glucocorticoids). ...

Phase

4.01 miles

Learn More »

Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy

This is a Phase 3, double-blind, randomized, placebo-controlled, study in patients aged 18 years and above with a biopsy-confirmed diagnosis of IgAN and with 24-hour UPE that is > 1 g/day within 6 months prior to Screening or uPCR > 0.75 by spot urine at Screening. During the study, all ...

Phase

4.01 miles

Learn More »

Efficacy and Safety of Four Doses of Cenerimod Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus

This is a Phase 2b, multicenter, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of 4 doses of cenerimod versus placebo in adult subjects with moderately to severely active, autoantibody-positive systemic lupus erythematosus (SLE). Approximately 500 adult subjects with SLE will be randomized in a 1:1:1:1:1 ratio ...

Phase

4.01 miles

Learn More »

The Psychosocial Effects of Systemic / Family Constellation

The purpose of this study is to investigate the psychosocial effects of systemic / family constellation. The method of systemic / family constellation refers to an approach which integrates ideas from family systems therapy with elements from psychodrama. The constellations are conducted in a group based seminar-setting, each seminar lasting ...

Phase N/A

4.35 miles

Learn More »

Fabry Disease Registry

The Fabry Registry is an international program; in addition to the central contact information provided under the "Location" heading, patients may contact: In Asia-Pacific - Vivian Liu, +65-6431-2548, Vivian.liu@genzyme.com In Europe - +31-35-699-1232, europe@FabryRegistry.com In Latin America - +617-591-5500, help@FabryRegistry.com In North America - +617-591-5500, help@FabryRegistry.com

Phase N/A

5.12 miles

Learn More »

Study of Safety of QAW039 in Patients With Asthma Inadequately Controlled on Standard-of-care Asthma Treatment

This study is a 2-treatment period, randomized, multicenter parallel-group study. The overall purpose of this study is to provide long- term safety data for fevipiprant (QAW039) (Dose 1 and Dose 2), compared with placebo, when added to the Global Initiative for Asthma (GINA) steps 3, 4, and 5 standard-of-care (SoC) ...

Phase

5.4 miles

Learn More »

This study is evaluating the efficacy of obinutuzumab in combination with chlorambucil (Arm A) compared with ACP-196 in combination with obinutuzumab (Arm B) for the treatment of previously untreated chronic lymphocytic leukemia (CLL). Arms Assigned Interventions Active Comparator: Obinutuzumab in Combination with Chlorambucil Obinutuzumab IV infusions will be administered over ...

Phase

5.69 miles

Learn More »